Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

More News From Technology - Malaysian Talks

China, US announce more trade talks next week

Feb 17, 2019

BEIJING — With a deadline looming, U.S. and Chinese negotiators will hold more talks in Washington next week aimed at ending a battle over Beijing's technology ambitions. The announcement Friday came after U.S. Trade Representative Robert Lighthizer told Chinese President Xi Jinping that negotiators "made headway" in talks this week in Beijing. They had been the last scheduled before planned U.S. penalties on $200 billion of Chinese products are due to take effect March 2. The United States "hopes to see additional progress," a White House statement said. It gave no indication whether President Donald Trump would extend the deadline....

Indonesia land-burning fines unpaid years after fires

Feb 17, 2019

JAKARTA, Indonesia — Indonesian plantation companies fined for burning huge areas of land since 2009 have failed to pay hundreds of millions of dollars in penalties meant to hold them accountable for actions that took a devastating environmental and human toll. The 10 palm oil and pulp wood companies involved in fires owe more than $220 million in fines and the figure for unpaid penalties for environmental destruction swells to $1.3 billion when an illegal logging case from 2013 is included, according to separate summaries of the cases compiled by Greenpeace and the Ministry of Environment and Forestry. Indonesia's annual...

The Latest: China's Xinhua: US trade talks for next week

Feb 17, 2019

BEIJING — The Latest on China-U.S. trade talks in Beijing (all times local): 6:40 p.m. An official Chinese news agency says U.S. and Chinese negotiators will meet next week in Washington for talks on a technology dispute ahead of a March 2 deadline for a planned American tariff hike. The Xinhua News Agency's announcement followed two days of talks in Beijing that had been the last scheduled meeting before the March 2 deadline. President Donald Trump's economic adviser said earlier he had yet to decide whether to escalate the dispute by going ahead with the penalties on $200 billion of...

China, US open trade talks as Beijing says exports rebound

Feb 17, 2019

BEIJING — U.S. and Chinese negotiators opened talks Thursday on a sprawling trade dispute as Beijing reported its January exports rebounded despite President Donald Trump's tariff hikes. Trump said earlier the talks could help decide whether he escalates the fight over China's technology ambitions by going ahead with more penalty duties March 2 on $200 billion of Chinese goods. The battle between the two biggest economies has fueled fears it will drag on weakening global growth. China's economy grew at its slowest pace in three-decades last year, adding to pressure on communist leaders to reach a settlement. Both sides have...

China, US start trade talks ahead of March tariff deadline

Feb 17, 2019

BEIJING — U.S. and Chinese negotiators began trade talks Thursday that President Donald Trump says will help decide whether he escalates a fight over Beijing's technology ambitions by raising tariffs on $200 billion of imports from China. Businesspeople and economists say the two days of talks are unlikely to resolve the battle that threatens to drag on weakening global economic growth. They say Chinese negotiators are trying to persuade Trump they are making enough progress to postpone a March 2 deadline for the duty increase. The chief American envoy, Trade Representative Robert Lighthizer, and his Chinese counterpart, Vice Premier Liu...